ZOMEDICA CORP (ZOM)

Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024

Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform

Noble Capital Markets Initiates Equity Research Coverage on Zomedica

Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024

Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform

Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET

Zomedica Announces Sponsorship of Educational Presentations at the Fetch Coastal Conference

Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe

Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota

Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities

Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product

Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System

Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference

ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024

ZOM stock results show that Zomedica missed on revenue for the second quarter of 2024.

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA

Zomedica Expands Global Reach Through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets

7 ‘Lottery Ticket Stocks’ That Could Turn $1K into $10K

Aggressive investors take note: these seven high-risk. high-reward stocks have the potential to rise in value by as much as 1,000%.

US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians

Zomedica Expands TRUFORMA Addressable Market with Launch of Equine Cortisol Assay for the Platform

Zomedica Expands Market Opportunity for the TRUFORMA Point-of-Care Diagnostic Platform by Securing CE Mark

The 3 Most Undervalued Penny Stocks to Buy in June 2024

Numerous penny stocks are undervalued and might benefit from elevated trading activity, given their fundamental zeal.

Sidoti Events, LLC's Virtual June Small-Cap Conference

Zomedica to Present at the Sidoti Small Cap Conference June 12, 2024

Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference

Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels

Zomedica Enhances TRUFORMA(R) Platform With Launch of Advanced Canine Cortisol Assay

Zomedica Publishes White Paper Highlighting Expanded Market Opportunities for PulseVet(R) Therapy

Zomedica to Present at the Lytham Partners Spring 2024 Investor Conference on May 30, 2024